ALKBH5 and cancer: Above all, everolimus, a pharmacological mTOR inhibitor widely used for advanced pNENs patient treatment, the lower expression of ALKBH5 may further synergize with everolimus to suppress mTOR activation and inhibit cancer cell growth.